Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome

Pathology

Volumn 42, Issue 7, 2010, Pages 664-668

  Sulzbacher, Irene ^a   Birner, Peter ^a   Dominkus, Martin ^a   Pichlhofer, Bettina ^a   Mazal, Peter R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Mutation; Osteosarcoma; PDGFRA; Prognosis

Indexed keywords

EID: 78649261532     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.520310     Document Type: Article

References (24)

1. st ed. St Louis: Mosby, 1998;128-252.
2. Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: The COSS experience. Cancer Treat Res 2010;152:289-308.
3. Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004;429:286-91.
4. Kaste SC, Liu T, Billups CA, et al. Tumour size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004;43:723-8.
5. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84:113-21.
6. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004;22:16-24.
7. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a predictive, multicenter study. J Clin Oncol 2005;23:1483-90.
8. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005;65:1748-54.
9. Sulzbacher I, Träxler M, Mosberger I, et al. Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000;13:632-37.
10. Sulzbacher I, Birner P, Trieb K, et al. Expression of Platelet-Derived Growth Factor-AA is associated with tumour progression in osteosarcoma. Mod Pathol 2003;16:66-71.
11. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
12. de Mestier P, des Guetz G. Treatment of gastrointestinal stroma tumors with imatinib mesylate: a major breakthrough in the understanding of tumour-specific molecular characteristics. World J Surg 2005;29:357-61.
13. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutation analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
14. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008;112:2119-29.
15. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumours. Pathologe 1983;4:135-41.
16. McGary EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8:3584-91.
17. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylateinchildren with refractoryorrelapsed solid tumours: a Children'S Oncology Group study. Pediatr Blood Cancer 2008;50:254-8.
18. Wang LF, Zhou Y, Xu YM, et al. A caspase-6 and anti-HER2 antibody chimeric tumour-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009;27:774-80.
19. Scotlandi K, Picci P. Targeting insulin like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20:419-27.
20. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009, 14:83-91.
21. Haluska P, Shaw HM, Natzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumours. Clin Cancer Res 2007;13:5834-40.
22. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP2 3573; MK-8669) administrated intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7.
23. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010;16:530-40.
24. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapyresistent sarcoma and osteosarcoma. Mol Ther 2009;17:1651-7.